# US 2025/0082779 A1 · Adeno-associated virus compositions having increased brain enrichment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082779 A1
- Document ID: US20250082779A1
- Status: Published application
- Kind: A1
- Application number: 18/284,409
- Filed: 2022-04-13
- Published: 2025-03-13
- Earliest claimed: 2021-04-13
- Assignees: Capsida, Inc.
- Applicants: Capsida, Inc.
- Inventors: Nicholas C. Flytzanis; Nicholas S. Goeden; Troy E. Sandberg; Brandon G. Wheeler
- Web page: https://patentgrep.com/patent/US20250082779A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2750/14152: relating to complementing cells and packaging systems for producing virus or viral particles
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with increased transduction enrichment in the CNS. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. Gene therapy using the rAAVs is described. Also described are methods of treating CNS-related diseases and conditions.

## Claims

### Claim 1

An AAV capsid protein comprising a sequence as provided in Table 1 or FIG. 1.

### Claim 2

An AAV capsid comprising an insertion sequence of Formula I
(I)
(SEQ ID NO: 2)
X1-N-X2-X3-X4-X5-X6
wherein X1 is an amino acid selected from A, S, G, N, L, Y, H, D, E, Q, P, T and V; X2 is an amino acid selected from Q, S, V, T, N, H and A; X3 is an amino acid selected from I, V and T; X4 is an amino acid selected from K and R; X5 is an amino acid selected from N, V, P, I, T, S, Q, A, L and G; and X6 is an amino acid selected from I, S, T, L, V, M, Y, F, A and N.

### Claim 3 (depends on 2)

The AAV capsid protein of claim 2, wherein X4 is K.

### Claim 4 (depends on 2)

The AAV capsid protein of claim 2, wherein X4 is R.

### Claim 5 (depends on 2)

The AAV capsid protein of claim 2, wherein X3 is V.

### Claim 6 (depends on 2)

The AAV capsid protein of claim 2, wherein X3 is T.

### Claim 7 (depends on 2)

The AAV capsid protein of claim 2, wherein X3 is I.

### Claim 8 (depends on 2)

The AAV capsid protein of claim 2, wherein X2 is Q.

### Claim 9 (depends on 2)

The AAV capsid protein of claim 2, wherein X1 is an amino acid selected from A, S, G, N, L, Y, D, E, Q, P, T and V.

### Claim 10 (depends on 2)

The AAV capsid protein of claim 2, wherein X3 is T or I when X1 is A.

### Claim 11 (depends on 2)

The AAV capsid protein of claim 2, wherein X3 is T or I when X1 is N.

### Claim 12 (depends on 2)

The AAV capsid protein of claim 2, wherein X2 is an amino acid selected from Q, S, V, T, N, H and A when X1 is D.

### Claim 13 (depends on 2)

The AAV capsid protein of claim 2, wherein X2 is an amino acid selected from Q, S, T, N, H and A.

### Claim 14 (depends on 2)

The AAV capsid protein of claim 2, wherein X6 is an amino acid selected from I, S, T, L, V, Y, A and N.

### Claim 15

An AAV capsid protein comprising an insertion sequence of Formula II
(II)
(SEQ ID NO: 3)
X7-N-H-V-R-X8-X9
wherein X7 is an amino acid selected from A, S, G, N, L, Y, H, D, E, Q, P, T and V; X8 is an amino acid selected from N, V, P, I, T, S, Q, A, L and G; and X9 is an amino acid selected from I, S, T, L, V, M, Y, F, A and N.

### Claim 16

An AAV capsid protein comprising an AAV capsid protein comprising an insertion sequence of Formula III
(III)
(SEQ ID NO: 4)
X10-N-V-X11-X12-X13-X14
wherein X10 is an amino acid selected from A, S, G, N, L, Y, H, D, E, Q, P, T and V; X11 is an amino acid selected from V and T; X12 is an amino acid selected from K and R; X13 is an amino acid selected from N, V, P, I, T, S, Q, A, L and G; and X4 is an amino acid selected from I, S, T, L, V, M, Y, F, A and N.

### Claim 17

An AAV capsid protein comprising an AAV capsid protein comprising an insertion sequence of Formula IV
(IV)
(SEQ ID NO: 5)
X15-N-T-X16-X17-X18-X19
wherein X15 is an amino acid selected from A, S, G, N, L, Y, H, D, E, Q, P, T and V; X16 is an amino acid selected from I, V and T; X17 is an amino acid selected from K and R;
X1a is an amino acid selected from N, V, P, I, T, S, Q, A, L and G; and X19 is an amino acid selected from I, S, T, L, V, M, Y, F, A and N.

### Claim 18

An AAV capsid protein comprising an AAV capsid protein comprising an insertion sequence of Formula V
(V)
(SEQ ID NO: 6)
X20-N-X21-V-R-X22-X23
wherein X20 is an amino acid selected from A, S, G, N, L, Y, H, D, E, Q, P, T and V; X21 is an amino acid selected from Q, S, V, T, N, H and A; X22 is an amino acid selected from N, V, P, I, T, S, Q, A and L; and X23 is an amino acid selected from I, S, T, L, V, M, Y, F and A.

### Claim 19

An AAV capsid protein comprising an AAV capsid protein comprising an insertion sequence of Formula VI
(VI)
(SEQ ID NO: 7)
X24-N-X25-T-K-X26-X27
wherein X24 is an amino acid selected from A, S, L, N, H, D, E, P, T and V; X25 is an amino acid selected from Q, S, V, T and N; X26 is an amino acid selected from N, V, P, T, S, Q and G; and X27 is an amino acid selected from I, S, T, L, V, M, Y, F, A and N.

### Claim 20 (depends on 19)

The AAV capsid protein of claim 19, wherein X24 is V, N, L and E.

### Claim 21

An AAV capsid protein comprising an insertion sequence of Formula VII
(VII)
(SEQ ID NO: )
X28-N-X29-T-R-X30-X31
wherein X28 is an amino acid selected from A, S, G, N, L, H, P, T and V; X29 is an amino acid selected from Q, S, V, T and H; X30 is an amino acid selected from N, V, T, S, Q, L and G; and X31 is an amino acid selected from I, S, T, V, M, Y, F, A and N.

### Claim 22 (depends on 21)

The AAV capsid protein of claim 21, wherein X29 is T or Q.

### Claim 23 (depends on 21)

The AAV capsid protein of claim 21, wherein X31 is an amino acid selected from T, V and N.

### Claim 24 (depends on 1)

The AAV capsid protein of claim 1, wherein the sequence is selected from GNTTRVT (SEQ ID NO: 9), LNSVRNT (SEQ ID NO: 10), NNNTKPS (SEQ ID NO: 11), GNSIKVV (SEQ ID NO: 12), GNSVRIS (SEQ ID NO: 13), ENHVRSS (SEQ ID NO: 14), SNTTRQT (SEQ ID NO: 15), TNSVKAT (SEQ ID NO: 16), GNTTRLV (SEQ ID NO: 17), SNSVRLV (SEQ ID NO: 18), ENSTKSL (SEQ ID NO: 19), ANSTRTT (SEQ ID NO: 20), PNQTRNN (SEQ ID NO: 21), QNSVKGY (SEQ ID NO: 22), GNHVRLA (SEQ ID NO: 23), VNSTKST (SEQ ID NO: 24), and DNSIRSS (SEQ ID NO: 25).

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The AAV capsid protein of any of claims 1-24 wherein the AAV is AAV9.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The AAV capsid protein of any of claims 1-25 wherein the AAV is provided in SEQ ID NO: 1

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The AAV capsid protein of any of claims 1-26 wherein the insertion is between amino acid 588 and amino acid 589.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The AAV capsid protein of any one of claims 1-27, wherein 60 copies of the AAV capsid protein are assembled into the AAV capsid.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The AAV capsid protein of any of claims 1-28, wherein the AAV capsid protein is present in VP1, VP2, and VP3 of the AAV capsid.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The AAV capsid protein of any of claims 1-29, wherein the AAV capsid protein is characterized by at least one of an increased transduction enrichment when measured in a CNS in a subject when delivered to the subject systemically.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The AAV capsid protein any of claims 1-30, wherein the AAV capsid protein further comprises an amino acid substitution comprising A589N or Q590P.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

An AAV capsid comprising an AAV capsid protein of any of claims 1-31.

### Claim 33 (depends on 32)

The AAV capsid of claim 32, wherein the AAV capsid is chimeric.

### Claim 34 (depends on 32, 33)

The AAV capsid of any of claims 32-33 that is isolated and purified.

### Claim 35 (depends on 32, 33, 34)

The AAV capsid of any of claims 32-34 formulated as a pharmaceutical formulation for systemic administration to treat a disease or a condition of the CNS, the pharmaceutical formulation further comprising a pharmaceutically acceptable carrier.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The AAV capsid protein of any of claims 1-31, wherein the capsid protein is expressed in the CNS.

### Claim 37 (depends on 36)

The AAV capsid protein of claim 36, wherein the CNS comprises a cell-type selected from a neuron, an oligodendrocyte, an astrocyte, and a brain vascular cell.

### Claim 38 (depends on 36, 37)

The AAV capsid protein of any one of claims 36-37, wherein the CNS comprises a tissue that is selected from brain, thalamus, cortex, putamen, lateral ventricles, medulla, the pons, the amygdala, the motor cortex, caudate, hypothalamus, striatum, ventral midbrain, neocortex, basal ganglia, hippocampus, thalamus, cerebrum, cerebellum, brain stem, and spinal cord.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A nucleic acid sequence encoding the peptide of any of claims 1-31, selected from the group consisting of SEQID NOs 57-73.

### Claim 40

A nucleic acid sequence encoding a peptide sequence as provided in Table 1 or FIG. 1.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A recombinant vector comprising a nucleic acid encoding the AAV capsid protein of any one of claims 1-31.

### Claim 42 (depends on 41)

A kit comprising:
a) a first vector comprising the recombinant vector of claim 41;
b) a second vector encoding a helper virus protein; and
c) a third vector comprising a therapeutic nucleic acid encoding a therapeutic gene expression product.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A method of treating a disease or condition in a subject comprising administering a therapeutically effective amount of a pharmaceutical formulation comprising the AAV capsid protein of any one of claims 1-31.

### Claim 44 (depends on 43)

The method of claim 43, wherein the disease or the condition is a disease or a condition of a CNS of the subject.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A method of manufacturing a recombinant AAV particle from the AAV capsid of any one of claims 1-31, the method comprising:
a. introducing into a cell a nucleic acid comprising:
i.a first nucleic acid sequence encoding a therapeutic gene expression product;
ii.a second nucleic acid sequence encoding a recombinant viral genome comprising a capsid (Cap) gene modified to express the AAV capsid of any one of claims 1-31; and
iii.a third nucleic acid sequence encoding an AAV helper virus genome; and
b. assembling the recombinant AAV particle, the recombinant AAV particle comprising the AAV capsid encapsidating the first nucleic acid.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The AAV capsid protein of any of claims 1-31 wherein the AAV capsid protein is characterized by an increased transduction enrichment when measured in a tissue in a subject when delivered to the subject systemically.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The AAV capsid protein of any of claims 1-31 wherein the tissue is brain tissue.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

An AAV particle comprising an AAV capsid protein of any of claims 1-31 and a viral genome.

### Claim 49

A peptide comprising an amino acid sequence selected from GNTTRVT (SEQ ID NO: 9), LNSVRNT (SEQ ID NO: 10), NNNTKPS (SEQ ID NO: 11), GNSIKVV (SEQ ID NO: 12), GNSVRIS (SEQ ID NO: 13), ENHVRSS (SEQ ID NO: 14), SNTTRQT (SEQ ID NO: 15), TNSVKAT (SEQ ID NO: 16), GNTTRLV (SEQ ID NO: 17), SNSVRLV (SEQ ID NO: 18), ENSTKSL (SEQ ID NO: 19), ANSTRTT (SEQ ID NO: 20), PNQTRNN (SEQ ID NO: 21), QNSVKGY (SEQ ID NO: 22), GNHVRLA (SEQ ID NO: 23), VNSTKST (SEQ ID NO: 24), and DNSIRSS (SEQ ID NO: 25).

### Claim 50

A recombinant adeno-associated virus (rAAV) comprising a capsid comprising any one of GNTTRVT (SEQ ID NO: 9), LNSVRNT (SEQ ID NO: 10), NNNTKPS (SEQ ID NO: 11), GNSIKVV (SEQ ID NO: 12), GNSVRIS (SEQ ID NO: 13), ENHVRSS (SEQ ID NO: 14), SNTTRQT (SEQ ID NO: 15), TNSVKAT (SEQ ID NO: 16), GNTTRLV (SEQ ID NO: 17), SNSVRLV (SEQ ID NO: 18), ENSTKSL (SEQ ID NO: 19), ANSTRTT (SEQ ID NO: 20), PNQTRNN (SEQ ID NO: 21), QNSVKGY (SEQ ID NO: 22), GNHVRLA (SEQ ID NO: 23), VNSTKST (SEQ ID NO: 24), and DNSIRSS (SEQ ID NO: 25).
